LIVE: Mylan CEO Heather Bresch confronts a furious Congress about EpiPen's price hike

Heather Bresch, the CEO of Mylan - which makes the EpiPen - is testifying in front of the House Oversight and Government Reform Committee Wednesday afternoon at 2 p.m. about the drug's price.

The price device, used in emergencies to treat severe allergic reactions, has increased more than 500% since Mylan acquired it in 2007. A two-pack of the EpiPen now has a list price of $608.

In her prepared testimony released ahead of the hearing, Bresch gave a background on Mylan as a company, and addressed some of the controversy around the rising price.

"Looking back, I wish we had better anticipated the magnitude and acceleration of the rising financial issues for a growing minority of patients who may have ended up paying the full [list] price or more," Bresch said in her testimony. "We never intended this."

You can watch the whole thing live here.

The congressmen are going to have a lot of questions for Bresch, who will be testifying alongside FDA deputy director Dr. Doug Throckmorton. In her defense, she says the company is implementing a number of programs to help patients pay for EpiPens.